We once again had a great turnout of #radonc physician-scientists at this year’s *12th* annual Community for Radiation Oncology Physician Scientists #CROPS 🌽 happy hour!

It’s always a highlight of ASTRO to connect with old friends and make new ones!

See you in Boston! #ASTRO25 #ARRO

34,000ft in the air en route to #ASTRO25.

This totally a word normal people use on a day to day basis, right? 😬🤞🏽

😑

We used a full length Ab specific to CD24 to engineer an #immunoPET agent and saw good localization to CD24+ HCC xenograft tumors!

BUT the liver uptake is a problem, esp if we want to image liver tumors!

Through some in silico sleuthing and literature searches, we were intrigued by CD24 as possible #radiopharmaceuticals target for #HCC.

We confirmed CD24 expression in several HCC cell lines by western blot and flow cytometry (NB: note diff between total protein and plasma membrane expression)

Proofs just hit!

👇

Happy proofs day to those who celebrate…

Details forthcoming!

#radiopharmaceuticals #theranostics #hcc

Next, is Divya!

We recruited her from UIUC with an amazing rec from her mentor Rita Miller!

During her 3 yrs, she working closely with all-star collaborator TJ Esparza established our de novo nanobody discovery efforts.
4/8

First up, Julia! We recruited her from the Morris’ lab at the UW Madison. During her 2 yrs, she worked across several projects, but her main project was assessed the potential of an understudied #HCC selective target for #radiotheranostics (under review) !
2/8

Stoked to brush up on my #radonc clinical fundamentals with Drs. Cuaron and Braunstein!

Hopefully, having a one-of-a-kind autographed issue will help internalize the wisdom.

Sans subscription, not sure.

The tl;dr:

One final note: You'll notice that in the RNAseq data of PDXs/PDOs, there's another target we highlighted #DLL3, which is also expressed in SCLC and NEPC and is being pursued as a target for these cancers including #radiotheranostics

doi.org/10.1016/S147...

And when tested one of our #GPC3-selective #radiotheranostics pairs, we observed nice localization and therapeutic benefit in H660 xenograft models!

For this story, we asked whether we could explore expression in patient samples (PDXs, PDOs, cell lines, IHC of tumors) more sytematically and whether we could use #GPC3 as a #radiopharmaceutical target for #NEPC.

Turns out that GPC3 is highly enriched in patients with AR-/NE+ prostate cancers!

🚨New publication alert🚨

Typeset version of our most recent publication in European Urology just hit!

Wonderful collaboration with @mishabeltran.bsky.social @adam-sowalsky.bsky.social and Pete Nelson at @fredhutch.bsky.social!

👇

Had fun collaborating with Ravi Patel and Steve Adler on this commentary highlighting Rob Flavell's and recent publication showing superior efficacy of alpha #radiopharmaceuticals therapy in micro v macromets in models of disseminated prostate ca

👇
1/3

Some news

At the end of the month, I will be leaving the NCI after nearly 9 years.

🧵
1/5

Great mid-week news on the publication front!

Could it be that our GPC3-selective radiotheranostics agents aimed at #HCC could be repurposed for neuroendocrine prostate cancer?

Fun collaboration with Dr. Adam Sowalsky, Himisha Beltran and Peter Nelson!

Stay tuned!

#radiopharmaceuticals #pcsm

We've got something brewing for education of #radonc on #radiopharmaceuticals...

Stay tuned!

cc @ijrobp.bsky.social

I spy a novel alpha-emitting GPC3-targeted antibody…

#radiopharmaceuticals #HCC #cancer

www.linkedin.com/pos...

And finally a massive effort by members of the #RPT Committee (@ASTRO_org @astro-org.bsky.social) yielded a white paper on patient safety focused on #radiopharmaceuticals therapy.

doi.org/10.1016/j.pr...
5/5

Next, we have a collaboration with Ravi Patel and Rosa Nguyen targeting VLA-4 (aka a4B1 integrin) as a pan cancer target for #radiopharmaceuticals therapy (RPT). This work builds on Ravi's prior work showing that low-dose RPT can facilaite IO tx

link: doi.org/10.1158/1535...
4/5

Next up, a collaboration with Ross Cheloha's group (@rche54 <a href="https://bsky.app/profile/did:plc:ycxfqyv32syaeu347y4xquiw" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky-mention">@rche54.bsky.social) and @MitchellHo leveraging a novel self-labeling approach for site-specific modification of nanobodies for biological applications.

doi.org/10.1002/advs...
3/5

First up, a collaboration lead by amazing staff scientist, Orit Jacobon-Weiss, demonstrating that developed a way to mitigate the typical kidney uptake/persistance of low molecular weight biomolecules using 18F-pyridine-based radiolabeling.

Link: doi.org/10.1021/acs....

2/5

Great listen and somehow timely